Lipoprotein Metabolism and Bacterial Lipopolysaccharide in Parkinson's Disease (LiMBaLiP)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03937284 |
|
Recruitment Status :
Completed
First Posted : May 3, 2019
Last Update Posted : May 3, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Patients with Parkinson's disease (PD) present an impaired intestinal permeability with consequent lipopolysaccharide (LPS) translocation in the systemic circulation. Plasmatic lipoproteins play a key role in the detoxification of LPS.
The investigators aim to study the relationships between lipoprotein chemical composition and plasma LPS circulation in PD.
| Condition or disease | Intervention/treatment |
|---|---|
| Parkinson Disease | Other: Patients not treated |
Bacterial lipopolysaccharides are able to produce neuroinflammation and dopaminergic receptors degeneration. In addition, they may produce an accumulation of α-synuclein in the area of the substantia Nigra. Recent studies have shown that α-synuclein aggregates may be present also in gastrointestinal neurons of patients with PD. This last finding led to the hypothesis that the intestine might be an early site of PD disease in response to an environmental toxin or pathogen. Forsyth et al. have discovered an impaired intestinal permeability in subjects with recently diagnosed PD, and they found positive correlations between this factor, exposure to LPS and alpha-synuclein accumulation in gastrointestinal neurons. Plasma lipoproteins play a key role in the detoxification of bacterial endotoxins. Lipoprotein chemical composition is related to their detoxing properties. To the best of investigator knowledge, the relationships between lipoprotein chemical composition and LPS in PD have not yet been investigated. Therefore, the aims of this study are: I) to evaluate the chemical composition of VLDL, LDL and HDL in subjects with PD compared to a control group; 2) to analyze the activity of plasma lipid transfer proteins and LPS plasma levels in the same groups of subjects; III) finally, to investigate the correlations between the analyzed parameters.
Subjects and method Twenty patients with PD and twenty healthy controls were recruited for the study. Fasting blood samples were taken for routine laboratory analysis and for the separation of EDTA plasma. Plasma samples stored at -80°C until were used for lipoprotein isolation and analysis and for the measurement of lipid transfer protein and LPS levels.
| Study Type : | Observational |
| Actual Enrollment : | 45 participants |
| Observational Model: | Case-Only |
| Time Perspective: | Cross-Sectional |
| Official Title: | Lipoprotein Lipidic Composition, Lipopolysaccharide Binding Protein, and Bacterial Endotoxin Exposure in Parkinson's Disease: A Pilot Study |
| Actual Study Start Date : | May 3, 2016 |
| Actual Primary Completion Date : | October 20, 2017 |
| Actual Study Completion Date : | October 20, 2017 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Parkinson's patients
Patients with Parkinson disease evaluated in agreement with UK Brain Bank criteria
|
Other: Patients not treated |
|
Control group
Subject matched for sex, age and BMI
|
Other: Patients not treated |
- LPS [ Time Frame: through study completion an average of 1 year ]LPS plasma levels (EU/L)
- Lipoprotein chemical composition [ Time Frame: through study completion an average of 1 year ]Cholesterol (mg/dL); HDL-cholesterol (mg/dL); triglycerides (mg/dL); phospholipids (mg/dL), apoproteins (mg/dL) of VLDL, LDL and HDL
- Plasma lipid transfer proteins [ Time Frame: through study completion an average of 1 year ]Lipopolysaccharide binding protein (ng/mL), cholesterol ester transfer protein (ng/mL), phospholipid transfer protein (ng/mL)
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Parkinson's patients
Inclusion Criteria:
- Diagnosis of Parkinson disease in agreement with UK Brain Bank
- Farmacological treatment with L-Dopa and/or dopaminergic agonist or diagnosis de novo
- BMI 18.5 - 29.9 kg/m^2
- Informed consent signature
Exclusion criteria:
- Presence of type 1 and type 2 diabetes mellitus
- Presence of major chronic diseases of the digestive tract.
- Pregnancy in progress
- Subjects subjected to antihypertensive therapies or statins or with drugs that can change metabolic status and insulin sensitivity (e.g. chronic oral steroid therapy)
- Subjects affected by endocrine pathologies (e.g. Cushing disease, uncontrolled thyroid disease)
- Presence of known renal insufficiency or creatinine levels greater than 1.8 mg/dl
- Presence of chronic liver disease or ALT and AST levels exceeding two standard deviations from normal levels
- Presence of malignant disease
- Alcohol or drug abuse
- Major psychiatric disorders
- Subjects dedicated to intense and agonistic physical activity.
Control group
Inclusion criteria
- Absence of major disease
- BMI 18.5 - 29.9 kg/m^2
- Informed consent signature
Exclusion Criteria:
- Presence of type 1 and type 2 diabetes mellitus
- Presence of major chronic diseases of the digestive tract.
- Pregnancy in progress
- Subjects subjected to antihypertensive therapies or statins or with drugs that can change metabolic status and insulin sensitivity (e.g. chronic oral steroid therapy)
- Subjects affected by endocrine pathologies (e.g. Cushing disease, uncontrolled thyroid disease)
- Presence of known renal insufficiency or creatinine levels greater than 1.8 mg/dl
- Presence of chronic liver disease or ALT and AST levels exceeding two standard deviations from normal levels
- Presence of malignant disease
- Alcohol or drug abuse
- Major psychiatric disorders
- Subjects dedicated to intense and agonistic physical activity.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03937284
| Italy | |
| ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO | |
| Milan, Italy, 20136 | |
| Principal Investigator: | Roberta Cazzola, PhD | University of Milan |
| Responsible Party: | roberta cazzola, Principal Investigator, University of Milan |
| ClinicalTrials.gov Identifier: | NCT03937284 |
| Other Study ID Numbers: |
Unimi |
| First Posted: | May 3, 2019 Key Record Dates |
| Last Update Posted: | May 3, 2019 |
| Last Verified: | May 2019 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Lipoproteins Lipopolysaccharide Lipopolysaccharide binding protein Inflammation |
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases |